Company Search:
Advanced Search
Sponsored Links
Lonza Group AG Company Snapshot
Lonza Group AG operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other pharmaceutical manufacturers in Europe: Jazz Pharmaceuticals Plc of IRELAND (2019 sales of 1.93 billion Euros [US$2.34 billion] of which 76% was Xyrem), H. Lundbeck A/S of DENMARK (17.04 billion Danish Kroner [US$2.77 billion] of which 100% was Pharmaceuticals), and Stada Arzneimittel AG which is based in GERMANY (2.61 billion Euros [US$3.16 billion] of which 59% was Generics).

Sales Analysis. During the year ended December of 2019, sales at Lonza Group AG were 5.92 billion Swiss Francs (US$6.61 billion). This is an increase of 6.8% versus 2018, when the company's sales were 5.54 billion Swiss Francs. This was the fifth consecutive year of sales increases at Lonza Group AG (and since 2014, sales have increased a total of 63%). Sales of Eliminations saw an increase that was more than double the company's growth rate: sales were up 57.9% in 2019, from 38.00 million Swiss Francs to 60.00 million Swiss Francs. Lonza Group AG also saw significant increases in sales in Pharma&biotech (up 33.9% to 4.17 billion Swiss Francs) . Not all segments of Lonza Group AG experienced an increase in sales in 2019: sales of Specialty Ingredients fell 29.2% to 1.69 billion Swiss Francs.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Lonza Group AG
  Stock Performance Chart for Lonza Group AG
  Stock Data: Recent Stock Performance:
  Current Price (11/30/2020): 569.60
(Figures in Swiss Francs)
1 Week 3.2%   13 Weeks 1.2%  
4 Weeks 1.6%   52 Weeks 70.6%  
Lonza Group AG Key Data:
  Ticker: LONN Country: Switzerland
  Exchanges: FRA GVA OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2019 Sales 5,920,000,000
(Year Ending Jan 2020).
Employees: 15,468
  Currency: Swiss Francs Market Cap: 40,893,264,534
  Fiscal Yr Ends: December Shares Outstanding: 74,108,852
  Share Type: Namenaktie Closely Held Shares: 82,279
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.